Clinical Trials
4
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2012
Completed
4
100.0%
No approval data available
- Ipsen reported H1 2026 total sales of €2.19 billion, representing 23.5% growth at constant exchange rates, and upgraded full-year 2026 sales growth guidance to greater than 20.0% at CER. - Positive Phase III results for Dysport in both episodic and chronic migraine prevention make it the first botulinum toxin to demonstrate efficacy across both indications in pivotal trials. - The Phase IIIb ELSPIRE study of Iqirvo in primary biliary cholangitis met its primary endpoint, with 85% of patients achieving ALP normalization at Week 52 versus 23% on placebo (p<0.0001). - Ipsen strengthened its pipeline through the acquisition of Memo Therapeutics AG (potravitug, a Phase II anti-BKPyV antibody) and a proposed acquisition of Kartos Therapeutics (navtemadlin, a Phase III oral MDM2 inhibitor for myelofibrosis).
- Ipsen SA agrees to acquire Memo Therapeutics AG for an initial €200 million, with total potential consideration reaching €700 million including deferred payments. - Schroders Capital Global Innovation Trust, an early investor in Memo Therapeutics, stands to receive up to £6.7 million from the transaction. - The deal is expected to close in the third quarter and validates Memo's antibody discovery platform and clinical-stage pipeline. - Proceeds from the upfront payment will contribute to Schroders Capital Global's planned capital return to shareholders, revised upward to £23.5 million.
- Memo Therapeutics' potravitug, a first-in-class anti-BKPyV monoclonal antibody, showed a 44.9% cumulative probability of viral clearance by week 20 versus 27.3% for matched controls (HR 1.89; p=0.028) in a propensity-score-matched analysis of the SAFE KIDNEY II trial. - The Phase II randomized, double-blind, placebo-controlled study employed an external control arm constructed from a multicenter kidney transplant cohort, with high-quality matching confirmed by absolute SMDs below 0.10 across all variables. - BK polyomavirus reactivates in up to 50% of kidney transplant recipients, with up to 70% of viremic patients developing BKPyV nephropathy, yet no approved treatments currently exist for this significant infectious complication. - MTx plans to initiate the pivotal SAFE KIDNEY 3 Phase III trial later in 2026, with potravitug having received FDA fast-track designation in May 2023 and EU orphan drug designation in December 2025.
- The European Commission granted orphan designation to potravitug, a BK polyomavirus-neutralizing antibody for treating infections in kidney transplant recipients. - The designation recognizes potravitug's potential to address a life-threatening condition affecting fewer than 5 in 10,000 people with no currently approved treatments. - Phase II SAFE KIDNEY trial data demonstrated sustained viral load reduction and resolution of BKPyV-associated nephropathy in kidney transplant recipients. - Memo Therapeutics plans to advance potravitug into Phase III clinical development in 2026, with potential market value up to $2 billion annually.
- Memo Therapeutics will present interim Phase II results for potravitug, a monoclonal antibody targeting BK polyomavirus infection in kidney transplant recipients, at the World Transplant Congress in August 2025. - The SAFE KIDNEY II trial enrolled 95 patients across 22 U.S. sites to evaluate potravitug's efficacy against BKPyV infection, which affects up to 50% of kidney transplant recipients. - Potravitug represents a potential first-in-class therapy for BKV infection, addressing a significant unmet medical need with no currently approved treatment options available. - The drug received FDA fast-track designation in May 2023, recognizing the high medical need in this indication with market potential estimated at up to $2 billion annually.
- Memo Therapeutics published research in Frontiers in Pharmacology showing that intravenously administered therapeutic IgG antibodies can cross the kidney endothelial barrier and be detected in urine. - The study found that 0.015% (median) of serum rituximab concentration appears in urine, with levels reaching up to 4.2%, challenging previous assumptions about size-exclusion limitations. - These findings provide scientific support for the dosing strategy of potravitug, MTx's investigational anti-BK polyomavirus antibody currently in Phase II trials for kidney transplant recipients. - BKV nephropathy affects up to 70% of kidney transplant recipients with established BK viremia and is associated with compromised graft function and reduced long-term survival.
- Memo Therapeutics AG has completed enrollment in its Phase II clinical trial of potravitug for BK viremia in kidney transplant patients. - The randomized, double-blind, placebo-controlled study is evaluating the safety, tolerability, and efficacy of potravitug. - Topline data from the trial, which includes 22 sites in the U.S., is expected in mid-2025. - Potravitug has received fast-track designation from the FDA due to the high unmet need for BK viremia treatments.
- Memo Therapeutics AG has completed enrollment in its Phase II clinical trial of potravitug for BK viremia in kidney transplant patients. - The randomized, double-blind, placebo-controlled study will assess the safety, tolerability, and efficacy of potravitug, with topline data expected in mid-2025. - Potravitug received fast-track designation from the FDA, addressing the high unmet medical need for BK viremia treatments, as no disease-modifying therapies are currently available. - The Phase II trial, involving 90 participants across 22 US sites, is the largest placebo-controlled study to date for BKV treatment in kidney transplant recipients.
- Memo Therapeutics AG has completed enrollment in its Phase II clinical trial of potravitug for treating BK viremia in kidney transplant patients. - The randomized, double-blind, placebo-controlled study evaluates the safety, tolerability, and efficacy of potravitug, with topline data expected in mid-2025. - Potravitug received fast-track designation from the FDA, highlighting the high unmet need for effective treatments for BK viremia, which affects up to 50% of kidney transplant recipients. - The trial is the largest placebo-controlled study conducted for BK viremia, a severe infection increasing the risk of early graft loss.
- Memo Therapeutics AG has finished enrolling patients in its Phase II clinical trial of potravitug, a BKV-neutralizing antibody, for kidney transplant recipients. - The randomized, double-blind, placebo-controlled study will assess the safety, tolerability, and efficacy of potravitug, with topline data expected in mid-2025. - Potravitug has the potential to become the first disease-modifying therapy for BK viremia, addressing a significant unmet need in kidney transplant patients. - The FDA previously granted fast-track designation to potravitug, highlighting the urgent need for effective treatments for BK viremia.
